Stock Research: Charles River Laboratories

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Charles River Laboratories

NYQ:CRL US1598641074
51
  • Value
    22
  • Growth
    50
  • Safety
    Safety
    76
  • Combined
    46
  • Sentiment
    55
  • 360° View
    360° View
    51
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Charles River Laboratories International, Inc. is a drug development company that provides essential products and services globally to accelerate research and drug development. Its main businesses include Research Models and Services (Research Models, Research Model Services, Cell Solutions), Discovery and Safety Assessment (regulated and non-regulated DSA services, therapeutic discovery and optimization, in vitro and in vivo studies, laboratory support, consulting), and Manufacturing Solutions (Microbial Solutions, Biologics Solutions). It operates around the globe. In the last fiscal year, the company had 18600 employees, a market cap of $7584 million, profits of $1408 million, and revenue of $4050 million.

more

ANALYSIS: With an Obermatt 360° View of 60 (better than 60% compared with alternatives), overall professional sentiment and financial characteristics for the stock Charles River Laboratories are above average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Charles River Laboratories. The consolidated Sentiment Rank has a good rank of 83, which means that professional investors are more optimistic about the stock than for 83% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 76 or better than 76% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 20, meaning that the share price of Charles River Laboratories is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 49. ...read more

more
Index
D.J. US Health Care
S&P 500
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 8-Jun-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
22 63 51 37
Growth
50 29 31 55
Safety
Safety
76 42 20 12
Sentiment
55 19 86 43
360° View
360° View
51 12 34 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
18 3 70 57
Opinions Change
55 13 36 60
Pro Holdings
n/a 74 88 21
Market Pulse
43 26 67 58
Sentiment
55 19 86 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
22 63 51 37
Growth
50 29 31 55
Safety Safety
76 42 20 12
Combined
46 23 12 12
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
88 63 57 67
Price vs. Earnings (P/E)
7 73 68 45
Price vs. Book (P/B)
57 53 40 22
Dividend Yield
1 1 1 1
Value
22 63 51 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
53 42 23 42
Profit Growth
91 22 48 57
Capital Growth
26 63 25 30
Stock Returns
44 25 61 81
Growth
50 29 31 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
11 28 20 22
Refinancing
91 31 9 17
Liquidity
79 55 71 56
Safety Safety
76 42 20 12

Similar Stocks

Discover high‑ranked alternatives to Charles River Laboratories and broaden your portfolio horizons.

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

FedEx

NYQ:FDX
Country: USA
Industry: Air Freight & Logistics
Size: XX-Large
Full Stock Analysis

Penske Automotive

NYQ:PAG
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The value case is weak (expensive and low Growth Rank), but sentiment is strong and financing is safe. This scenario may indicate future growth not yet in current financials. This is a speculative choice for investors with a high-risk appetite who are betting on the positive sentiment and safe financing to sustain a long-term turnaround.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: